Cover Image
Market Research Report

Cardiac Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)

Published by Mordor Intelligence LLP Product code 567965
Published Content info 120 Pages
Delivery time: 2-3 business days
Back to Top
Cardiac Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)
Published: February 1, 2020 Content info: 120 Pages

Biomarkers enable the timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. According to WHO, around 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Myocardial infarction is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. A timely diagnosis of heart conditions allows clinicians to analyze the risk of their patients and prescribe relevant treatment. The increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements is expected to drive the market in the forecast period.

Key Market Trends

Myocardial Infarction Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Others. The key factor contributing to the growth of the segment is the rising number of cardiovascular disorders. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. The average age of first myocardial infarction is 65.6 years old for men and 72.0 years old for women. Many companies are focusing on developing breakthrough products for the treatment of cardiovascular disease. Hence, with the rising government initiatives and wide applications of biomarkers in cardiac diagnostics, the market is expected to grow over the forecast period.

North America Dominates the Cardiac Biomarkers Market

The cardiac biomarkers market holds the largest share in North America region. According to the American Heart Association around 2,300 Americans die of cardiovascular disease each day. The cardiac markers help in monitoring the prognosis of certain condition with greater accuracy and providing the most effective treatment to the patients Hence, with the rising concerns regarding cardiovascular disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Competitive Landscape

The global players in the cardiac biomarkers market are - Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 54449

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cardiovascular Diseases
    • 4.2.2 Technological Advancements in the Cardiac Biomarkers
    • 4.2.3 Growing Funding From Public and Private Organizations for R&D
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Creatine Kinase
    • 5.1.2 Troponins
    • 5.1.3 Myoglobin
    • 5.1.4 Ischemia Modified Albumin
    • 5.1.5 Others
  • 5.2 By Application
    • 5.2.1 Congestive Heart Failure
    • 5.2.2 Acute Coronary Syndrome
    • 5.2.3 Myocardial Infarction
    • 5.2.4 Atherosclerosis
    • 5.2.5 Others
  • 5.3 By Location Of Testing
    • 5.3.1 Point of Care Testing
    • 5.3.2 Laboratory Testing
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 BioMerieux
    • 6.1.4 Bio-Rad Laboratories, Inc.
    • 6.1.5 Danaher Corporation
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Randox Laboratories
    • 6.1.8 Siemens Healthineers
    • 6.1.9 Thermo Fisher Scientific


Back to Top